Korro Bio, Inc.

Listed Company

KRROCIK 0001703647NasdaqNon-AcceleratedSmaller ReportingPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

$6.39M

Net Income

$-117.26M

Total Assets

$113.51M

Equity

$51.44M

Shares Out

14.42M

Op. Cash Flow

$-78.56M

Business

Korro Bio, Inc. is a clinical-stage biopharmaceutical company that develops oligonucleotide-based ADAR-mediated RNA editing therapies. It offers proprietary RNA editing product candidates (CHORDs) built on its OPERA platform combining ADAR biology, oligonucleotide chemistry, machine learning and fit‑for‑purpose delivery. Key business activities include a clinical-stage AATD program (KRRO-110), and research/preclinical programs for a rare metabolic disorder, ALS (TDP‑43), and pain, along with collaborations such as a Novo Nordisk partnership. Korro Bio conducts trials and supplies candidates using established delivery modalities (LNP, GalNAc), CMOs, and global clinical sites including Australia and the United States.

Summary from filing dated 2025-03-18

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Collaboration revenue	6	2	0	—	—
Research and development	66	64	57	42	61
General and administrative	28	31	27	17	37
Long-lived asset impairment charge	31	0	—	—	—
Restructuring charge	4	0	—	—	—
Total operating expenses	128	94	85	59	98
Loss from operations	−122	−92	−85	−59	−84
Other income, net	5	8	3	976,000	—
Total other income, net	5	8	3	976,000	−266,000
Loss before provision for income taxes	−117	−83	−81	−58	−85
Provision for income taxes	−637,000	−141,000	−27,000	10,000	−15,000
Net loss	−117	−84	−81	−58	−85
Unrealized (loss) gain on available-for-sale marketable securities	−26,000	184,000	0	2,000	—
Foreign currency translation adjustments, net	−30,000	84,000	0	—	—
Comprehensive loss	−117	−83	−81	−58	—
Net loss per share, basic	−12.48	−9.37	−53.08	−227.42	—
Net loss per share, diluted	−12.48	−9.37	−53.08	−227.42	—
Weighted-average shares used in computing net loss per share, basic	9	9	2	255,175	—
Weighted-average shares used in computing net loss per share, diluted	9	9	2	255,175	—

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2023 2023-10-31	FY 2022 2022-12-31
Cash and cash equivalents	22	56	166	37	36
Short-term marketable securities	53	70	0	—	—
Accounts receivable	969,000	2	0	—	—
Prepaid expenses and other current assets	6	4	3	—	1
Total current assets	82	132	173	—	57
Property and equipment, net	8	28	16	—	10
Operating lease right-of-use assets	8	24	27	—	2
Restricted cash, net of current portion	2	3	3	—	5
Long-term marketable securities	10	37	0	—	—
Other non-current assets	2	3	3	—	228,000
Total assets	114	226	222	—	74
Accounts payable	2	4	7	—	3
Accrued expenses and other current liabilities	8	6	10	—	3
Operating lease liabilities, current portion	3	1	2	—	3
Deferred revenue, current portion	0	4	0	—	—
Total current liabilities	12	15	19	—	9
Operating lease liabilities, net of current portion	41	43	31	—	209,000
Deferred revenue, net of current portion	8	6	0	—	—
Other non-current liabilities	1	1	1	—	0
Total liabilities	62	66	52	—	9
Commitments and contingencies (Note 13)	—	—	—	—	—
Preferred stock, $0.001 par value; 10,000,000 shares authorized at December 31, 2025 and December 31, 2024; no shares issued and outstanding at December 31, 2025 and December 31, 2024	0	0	0	—	0
Common stock, $0.001 par value; 200,000,000 shares authorized at December 31, 2025 and December 31, 2024; 9,417,295 shares and 9,377,259 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively	9,000	9,000	8,000	—	0
Additional paid-in capital	435	427	353	—	3
Accumulated other comprehensive income	212,000	268,000	0	—	−5,000
Accumulated deficit	−384	−267	−183	—	−102
Total stockholders' equity	51	160	170	—	−99
Total liabilities and stockholders' equity	114	226	222	—	74

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net loss	−117	−84	−81	−58	−85
Non-cash lease expense	730,000	3	4	1	1
Stock-based compensation expense	8	4	2	1	—
Depreciation expense	4	4	4	3	3
Net amortization of premiums and discounts on marketable securities	−489,000	−2	−80,000	−145,000	—
Loss on disposal of property and equipment	63,000	357,000	65,000	0	16,000
Accounts receivable	727,000	−2	0	—	—
Prepaid expenses and other current assets	−2	−726,000	559,000	−28,000	−173,000
Accounts payable	−2	−1	3	2	−2
Accrued expenses and other current liabilities	1	−4	1	−39,000	−398,000
Deferred revenue	−2	9	0	—	—
Operating lease liabilities	−1	12	1	−2	−396,000
Other non-current assets	270,000	340,000	−2	−123,000	—
Net cash used in operating activities	−79	−60	−67	−54	−76
Purchases of marketable securities	−26	−146	0	−54	−92
Proceeds from maturities of marketable securities	71	41	19	53	—
Purchases of property and equipment	−518,000	−18	−8	−5	−3
Net cash provided by (used in) investing activities	44	−123	11	11	−66
Proceeds from PIPE financing, net of issuance costs	0	67	0	—	—
Proceeds from exercises of stock options	685,000	2	702,000	62,000	—
Net cash provided by financing activities	685,000	69	188	18,000	1
Effect of exchange rate changes on cash, cash equivalents and restricted cash	64,000	−4,000	0	—	—
Net decrease in cash, cash equivalents and restricted cash	−34	−114	132	−43	−141
Property and equipment capitalized under tenant improvement allowance	0	11	2	0	—
Purchases of property and equipment in accounts payable and accrued expenses	0	48,000	2	402,000	—
Cash paid for income taxes	1,000	141,000	27,000	11,000	—
Cash paid for operating lease liabilities	6	3	3	2	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro